US EditionPublished • loading... • Updated
Harrow, Inc. (HROW) Stock Analysis: Eye On Nearly 100% Upside With Strong Buy Ratings
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Harrow, Inc. (HROW) Stock Analysis: Eye On Nearly 100% Upside With Strong Buy Ratings
Investors looking for promising opportunities in the healthcare sector should consider Harrow, Inc. (NASDAQ: HROW), a key player in the niche market of ophthalmic pharmaceuticals. With a market capitalization of $1.31 billion, Harrow is poised for significant growth, supported by a bullish analyst outlook and a robust pipeline of products aimed at addressing various eye conditions. Harrow’s stock is currently trading at $35.15, having experience…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
